Epic Bio Presents Preclinical Data on EPI-321 for Facioscapulohumeral Muscular Dystrophy at ASGCT 26th Annual Meeting - Oral presentation highlights EPI-321 effects on multiple clinically relevant markers - - IND application for EPI-321 planned for 2023 - SOUTH SAN FRANCISCO, Calif., May 19, 2023 (GLOBE...

Epic Bio to Present Preclinical Data at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting SOUTH SAN FRANCISCO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Epic BIO, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...

SOLVE FSHD Invests in Epic Bio to Advance Potentially Curative Therapy SOUTH SAN FRANCISCO, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...